QYUNS-B buys back 0.11 million H-shares; treasury stock rises to 3.05 million units

Bulletin Express06-03

Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25 to HKD 16.30 per share, with a volume-weighted average cost of HKD 15.89, for a total outlay of HKD 1.69 million.

Following the transaction, issued shares outstanding (excluding treasury stock) fell 0.05 % to 224.03 million, while treasury shares increased to 3.05 million. Total issued share capital remains unchanged at 227.07 million shares.

The buyback forms part of the mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.34 million shares, equivalent to 0.15 % of the share count on the mandate date. A 30-day moratorium on new share issuance or treasury-share sales runs through 3 July 2026, in accordance with Hong Kong Stock Exchange rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129591150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129591150","market":"hk","top_or_hot":-1,"title":"QYUNS-B buys back 0.11 million H-shares; treasury stock rises to 3.05 million units","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25 to HKD 16.30 per share, with a volume-weighted average cost of HKD 15.89, for a total outlay of HKD 1.69 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury stock) fell 0.05 % to 224.03 million, while treasury shares increased to 3.05 million. Total issued share capital remains unchanged at 227.07 million shares.</p>\n<p>The buyback forms part of the mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.34 million shares, equivalent to 0.15 % of the share count on the mandate date. A 30-day moratorium on new share issuance or treasury-share sales runs through 3 July 2026, in accordance with Hong Kong Stock Exchange rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B buys back 0.11 million H-shares; treasury stock rises to 3.05 million units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B buys back 0.11 million H-shares; treasury stock rises to 3.05 million units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25 to HKD 16.30 per share, with a volume-weighted average cost of HKD 15.89, for a total outlay of HKD 1.69 million.</p>\n<p>Following the transaction, issued shares outstanding (excluding treasury stock) fell 0.05 % to 224.03 million, while treasury shares increased to 3.05 million. Total issued share capital remains unchanged at 227.07 million shares.</p>\n<p>The buyback forms part of the mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.34 million shares, equivalent to 0.15 % of the share count on the mandate date. A 30-day moratorium on new share issuance or treasury-share sales runs through 3 July 2026, in accordance with Hong Kong Stock Exchange rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1129591150","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129591150","pubTimestamp":1780485791,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"QYUNS-B回购11万股H股；库存增至305万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share repurchase on 3 June 2026, retiring 106,600 H-shares via on-market transactions. The repurchase was executed at prices ranging from HKD 15.25 to HKD 16.30 per share, with a volume-weighted average cost of HKD 15.89, for a total outlay of HKD 1.69 million.\nFollowing the transaction, issued shares outstanding (excluding treasury stock) fell 0.05 % to 224.03 million, while treasury shares increased to 3.05 million. Total issued share capital remains unchanged at 227.07 million shares.\nThe buyback forms part of the mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.34 million shares, equivalent to 0.15 % of the share count on the mandate date. A 30-day moratorium on new share issuance or treasury-share sales runs through 3 July 2026, in accordance with Hong Kong Stock Exchange rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129591150","isCrawlerRequest":true}